| Modag–SEVERAL: investment, 201906 financing round Series A €12m led by Massa Investment AG |
2019-06-27 |
| Modag–Trophic Communications: public relations, 201906 service existent by Trophic |
2019-06-27 |
| PhagoMed–SEVERAL: investment, 201906 2nd financing round €1.5m from existing + new investors |
2019-06-27 |
| Velabs Therapeutics–SEVERAL: investment, 201906 financing round Series B €3m |
2019-06-27 |
| Evotec–SEVERAL: credit, 201906– promissory note €250m with lead arrangers Deutsche Bank + LBBW |
2019-06-26 |
| Allergan–AbbVie: investment, 201905– acquisition $63b in cash + shares by AbbVie ANNOUNCED |
2019-06-25 |
| Vesalius Biocapital–SEVERAL: investment, 201906 final closing of €120m Vesalius Biocapital III fund |
2019-06-25 |
| Avacta–JSR Corp: cell line development, 201906– CHO cell line development for clinical manufacturing of AVA004 Affimer PD-L1 antagonist by Selexis |
2019-06-20 |
| Gamida Cell–Lonza: cell therapy contract manufacturing, 201906– supply multi-year future commercial production of omidubicel by Lonza in Geleen (NL) |
2019-06-19 |
| Germany (govt)–Trophic Communications: public relations, 201906 service existent for German Accelerator Life Sciences by Trophic |
2019-06-18 |
| Merck (DE)–SEVERAL: credit, 201906 hybrid €1.5b bond to finance acquisition of Versum Materials Inc |
2019-06-18 |
| ADC Therapeutics–SEVERAL: investment, 201906–201907 financing round Series E expansion $103m bringing total Series E to $303m |
2019-06-12 |
| Ipsen–Debiopharm: triptorelin, 201906– strategic collab extension 15y developm + prod + distrib Decapeptyl in Europe + certain Asia + Africa |
2019-06-12 |
| 4SC–SEVERAL: investment, 201906 capital increase €11m with 4.677m new shares at €2.37/share |
2019-06-11 |
| Binding Site–Tecan: laboratory automation, 201906 collab existent developm automated solution for using MALDI-MS to diagnose blood cancers |
2019-06-06 |
| HighChem–Thermo Fisher: investment, 201906 acquisition €na of HighChem Ltd by Thermo Fisher |
2019-06-06 |
| Merck (DE)–Rigaku: X-ray crystallography, 201906– collab developm of devices for use with Merck consumables using crystalline sponge technology |
2019-06-06 |
| Merck (DE)–Univ Tokyo: crystalline sponge technology, 201906– license for technolgoy invented by Prof Makoto Fujita |
2019-06-06 |
| Vertex–CRISPR Therapeutics: CRISPR technology, 201906– collab expansion $175m upfront + $825m milestones CRISPR for DMD + DM1 gene editing products |
2019-06-06 |
| MiniFab–Schott: investment, 201906– acquisition of MiniFab Pty Ltd by Schott |
2019-06-05 |
| Agilent–Frost & Sullivan: market research, 201906 supply service survey of pharma lab leaders on lab workflows by F&S |
2019-06-04 |
| Arvinas–Bayer: investment, 201906 direct equity investment in Arvinas Inc as part of collab in protein degradation drugs using PROTAC technology |
2019-06-04 |
| Bayer–Arvinas: protein degradation drugs, 201906– collab up to $745m developm of drug candidates using PROTAC technology |
2019-06-04 |
| Spindiag–SEVERAL: investment, 201906 financing round Series A exansion additional €4m incl new investor WBG Pflegeheime |
2019-06-04 |
| Yukin Therapeutics–SEVERAL: investment, 201906 financing round €3.3m co-led by Advent France Biotechnology + Medicxi |
2019-06-04 |
| Bruker–908 Devices: sample separation technology, 201906– collab integration of ZipChip microfluidics separation with Bruker TOF systems |
2019-06-03 |
| Otsuka–LeadXPro: structure-based drug discovery, 201906– collab strategic on membrane protein structure research of Astex + LeadXPro |
2019-06-03 |
| Bruker–Genedata: bioinformatics, 201905– collab product integration Genedata Expressionist supports timsTOF MS systems data |
2019-05-31 |
| Bruker–PreOmics: sample preparation technology, 201905– collab developm + marketing PreOmics iST sample preparation on timsTOF Pro MS system |
2019-05-31 |
| Helmholtz–Bruker: mass spectrometry software, 201905 supply existent HIPS long-time user of SCiLS Lab + MetaboScape s/w |
2019-05-31 |
| Medical Univ South Carolina–Bruker: mass spectrometer, 201905 supply existent timsTOF fleX system early customer Proteomics Center at Med Univ SC |
2019-05-31 |
| BlueHaven Therapeutics–MC Services: public relations, 201905 service existent IR by MC Services |
2019-05-30 |
| Bayer–Roche: molecular companion diagnostics, 201905– collab ww €na developm + commercialisation o fNGS-based CDx in oncology |
2019-05-29 |
| PHW-Gruppe–Ampersand: investment, 201905 acquisition of Vibalogics GmbH by Ampersand Capital Partners |
2019-05-29 |
| Biocrates–NONE: investment, 201905– bankruptcy filed for subsidiary Metanomics Health GmbH |
2019-05-22 |
| Cubuslab–Labfolder: investment, 201905 acquisition merger of Cubuslab Gmbh + Labfolder GmbH + new name Labforward GmbH |
2019-05-22 |
| JnJ–Owlstone: breath analyser, 201905– collab developm breath-based test for early detection of pulmonary hypertension with Actelion |
2019-05-20 |
| Just Biotherapeutics (US)–Evotec: investment, 201905–201907 acquisition 100% for $60m upfront + $30m upfront |
2019-05-20 |
| Storm Therapeutics–Merck (DE): investment, 201905 financing round Series A extension totalling £14m incl existing investor M Ventures |
2019-05-20 |
| Storm Therapeutics–SEVERAL: investment, 201905 financing round Series A extension £14m bringing total round to £30m incl new investor Seroba LS |
2019-05-20 |
| LabCentral–Harrison Street: business park, 201905 supply service existent LabCentral is anchor tenant at Osborn Triangle lab complex in Cambridge MA |
2019-05-17 |
| MIT–Harrison Street: business park, 201905 acquisition of Osborn Triangle complex by Harrision Street + Bulfinch from MIT with MIT retaining interest |
2019-05-17 |
| Novartis–Harrison Street: business park, 201905 supply service existent Novartis 1 of 3 anchor tenants at Osborn Triangle lab complex in Cambridge MA |
2019-05-17 |
| DNA Script–Life Sciences Partners: investment, 201905 financing round Series B totalling $38.5m incl new + lead investor LSP |
2019-05-16 |
| DNA Script–SEVERAL: investment, 201905 financing round Series B $38.5m led by LSP |
2019-05-16 |
| Inovio–Qiagen: molecular companion diagnostics, 201905– collab developm of CDx for VGX-3100 DNA-based immunotherapy for cervical dysplasia |
2019-05-16 |
| Roche–AbbVie: ventoclax, 201905 collab existent joint commercialisation in US as Venclexta by AbbVie + Genentech |
2019-05-16 |
| Navan Technologies–High-Tech Gründerfonds: investment, 201905 seed financing round incl Amgen Ventures + HTGF + Hemi Ventures et al |
2019-05-15 |
| Navan Technologies–SEVERAL: investment, 201905 seed financing round incl Amgen Ventures + HTGF + Hemi Ventures et al |
2019-05-15 |
| Navan Technologies–Stanford Univ: cell therapy technology, 201905 license excl existent to NanoStraw technology platform |
2019-05-15 |
| Novartis–Codexis: protein engineering technology, 201905– tech transfer + license agreem for CodeEvolver technology to be installed at a Novartis site |
2019-05-15 |
| Vaccitech–Minapharm: cell line, 201905– license to ProBioGen’s AGE1.CR duck cell line for production of viral vectored vaccines |
2019-05-15 |
| Icometrix–Bertarelli Group: investment, 201905 financing round totalling $18m incl new + lead investor Forestay Capital |
2019-05-14 |
| Icometrix–Capricorn Venture Partners: investment, 201905 financing round totalling $18m incl existing + co-investor Capricorn Venture Partners |
2019-05-14 |
| Icometrix–Optum Ventures: investment, 201905 financing round totalling $18m incl new + co-investor Optum Ventures |
2019-05-14 |
| Icometrix–SEVERAL: investment, 201905 financing round $18m led by Forestay Capital + incl Optum Ventures + Capricorn Venture Partners |
2019-05-14 |
| Philogen–Consilium: public relations, 201905 service existent by CSC |
2019-05-13 |
| Philogen–SEVERAL: investment, 201905 financing round €62m from existing + new private investors |
2019-05-13 |
| TreeFrog Therapeutics–SEVERAL: investment, 201905 financing round Series A €6.5m led by XAnge + incl Galia Geston et al |
2019-05-13 |
| Priavoid–PERSON: investment, 201905c Detlev Riesner recently acquired shares of Priavoid GmbH |
2019-05-10 |
| MabVax Therapeutics–BioNTech: investment, 201905 acquisition €na of antibody assets + infrastructure + lab equipment in San Diego |
2019-05-08 |
| Therachon–Cowen: investment, 201905 existing investor Cowen |
2019-05-08 |
| Therachon–France (govt): investment, 201905 existing investors Bpifrance + Inserm Transfert Initiative |
2019-05-08 |
| Therachon–Novo Group: investment, 201905 existing investor Novo Holdings |
2019-05-08 |
| Therachon–OrbiMed: investment, 201905 existing investor OrbiMed |
2019-05-08 |
| Therachon–Pfizer: investment, 201905 existing investor Pfizer Ventures |
2019-05-08 |
| Therachon–Pfizer: investment, 201905– acquisition 100% $340m upfront + $470m milestones excl apraglutide development program |
2019-05-08 |
| Therachon–Tekla Capital: investment, 201905 existing investor Tekla Capital Management LLC |
2019-05-08 |
| Therachon–Versant Ventures: investment, 201905 existing investor Versant Ventures |
2019-05-08 |
| Confo Therapeutics–SEVERAL: investment, 201905 financing round Series A €30m led by BGV + co-led by Wellington Partners |
2019-05-07 |
| Confo Therapeutics–Wellington Partners: investment, 201905 financing round Series A totalling €30m incl new + co-lead investor Wellington Partners |
2019-05-07 |
| DyNAbind–High-Tech Gründerfonds: investment, 201905 seed financing round incl new investor HTGF |
2019-05-07 |
| DyNAbind–Saxony (govt): investment, 201905 seed financing round incl new investor Technologiegründerfonds Sachsen |
2019-05-07 |
| DyNAbind–SEVERAL: investment, 201905 seed financing round from HTGF + TGFS + TUDAG |
2019-05-07 |
| DyNAbind–TU Dresden: investment, 201905 seed financing round incl existing investor TUDAG TU Dresden AG |
2019-05-07 |
| Merck (DE)–DyNAbind: drug discovery technology, 201905 collab existent marketing of DEL discovery kit with Merck KGaA |
2019-05-07 |
| Northwestern Univ–DyNAbind: drug discovery technology, 201905 collab existent with Northwestern Univ Chicago |
2019-05-07 |
| OMass–DyNAbind: drug discovery technology, 201905 collab existent with OMass Therapeutics |
2019-05-07 |
| Sosei–DyNAbind: drug discovery technology, 201905 collab existent with Sosei Heptares |
2019-05-07 |
| Cutech (IT)–Symrise: investment, 201905 acquisition of Cutech Srl by Symrise |
2019-05-06 |
| Intermolecular–Merck (DE): investment, 201905– acquisition of Intermolecular Inc by Merck for $62m in cash at $1.2/share |
2019-05-06 |
| Chemical Solutions Ltd–SGS: investment, 201905 acquisition of CSL by SGS |
2019-05-03 |
| Amal Therapeutics–Boehringer: cancer drugs, 201905– collab clinical research combi study of ATP128 + BI754091 in colorectal cancer |
2019-05-02 |
| CStone–Numab: antibody cancer drug, 201905– collab + license for tri-specific antibody ND021 in Greater China + KR + SG |
2019-05-02 |
| miRdetect–Bremen (govt): investment, 201905 seed financing round 7-digit € from HTGF + BBM Bremen + a private investor |
2019-05-02 |
| miRdetect–High-Tech Gründerfonds: investment, 201905 seed financing round 7-digit € from HTGF + BBM Bremen + a private investor |
2019-05-02 |
| miRdetect–OTHER: investment, 201905 seed financing round 7-digit € from HTGF + BBM Bremen + a private investor |
2019-05-02 |
| miRdetect–SEVERAL: investment, 201905 seed financing round 7-digit € from HTGF + BBM Bremen + a private investor |
2019-05-02 |
| Alentis Therapeutics–Bellevue: investment, 201904 financing round Series A totalling CHF12.5m incl co-lead investor BB Pureos Bioventures |
2019-04-30 |
| Alentis Therapeutics–BioMedPartners: investment, 201904 financing round Series A totalling CHF12.5m incl co-lead investor BioMedPartners |
2019-04-30 |
| Alentis Therapeutics–France (govt): investment, 201904 financing round Series A totalling CHF12.5m incl co-investor Bpifrance |
2019-04-30 |
| Alentis Therapeutics–High-Tech Gründerfonds: investment, 201904 financing round Series A totalling CHF12.5m incl co-investor HTGF |
2019-04-30 |
| Alentis Therapeutics–Instinctif Partners: public relations, 201904 service existent media relations by Instinctif |
2019-04-30 |
| Alentis Therapeutics–Schroders: investment, 201904 financing round Series A totalling CHF12.5m incl co-investor Schroder Adveq |
2019-04-30 |
| Alentis Therapeutics–SEVERAL: investment, 201904 financing round Series A CHF12.5m co-led by BioMedPartners + BB Pureos Bioventures |
2019-04-30 |
| SGS–Veeva Systems: clinical research software, 201904– supply global implementation of Veeva Vault CTMS by SGS |
2019-04-30 |
| Canopy Biosciences–Ampersand: investment, 201904 strategic growth investment from Ampersand Capital Partners |
2019-04-29 |
| Zellkraftwerk–Canopy Biosciences: investment, 201904 acquisition of Zellkraftwerk GmbH by Canopy Biosciences |
2019-04-29 |
| ADC Therapeutics–Adagene: antibody technology, 201904– collab + license agreem €na using SAFEbody technology for ADC development |
2019-04-24 |
| Chiome Bioscience–Velabs Therapeutics: antibody drug discovery, 201904– collab using Velabs’ microfluidcs techn for functional antibody screening |
2019-04-24 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
1 2 3 4 5 ... 53 54 55 
Date![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px](/banner/iito-20181119-650-065-lsus-life-sciences-usa-com.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
